

A

01/20/98
 jcs35 U.S. PTO

BULLWINKEL PARTNERS, LTD.

Attorneys Counselors

19 South LaSalle Street Chicago, Illinois 60603-1493

312.201.0777 fax 312.201.0737

http://www.Bullwinkel.com

hjf@Bullwinkel.com

HAROLD J. FASSNACHT

January 19, 1998

Commissioner of Patents and Trademarks
 BOX PATENT APPLICATION
 Washington, D.C. 20231

Re: New Patent Application
 1 α -HYDROXYVITAMIN D₅, ITS SYNTHESIS AND
 USE IN CANCER PREVENTION AND THERAPY
 (Priority Application No. 60/039,106 filed 02/25/97)
 Inventors: Moriarty, R.M.; Penmasta, R.; Guo, L.; Rao,
 M.S.; and Mehta, R.G.
 Assignee: Steroids, Ltd.

Dear Sir:

Transmitted herewith for filing is the patent application of R.M. Moriarty et al. as above identified. Enclosed are:

1. Specification and Claims;
2. Four sheets of drawings;
3. Declaration and Power of Attorney;
4. Verified Statement (Declaration) Claiming Small Entity Status (37 CFR 1.9(f) & 1.27(b)) -- Independent Inventors;
5. Assignment of Invention and Assignment Cover Sheet;
6. A check in the amount of \$435, representing the \$395 filing fee for a small entity, calculated as shown below and the \$40 Patent Assignment Recordation fee; and
7. A self-addressed stamped return postal card.

	(Col. 1)	(Col.2)	<u>SMALL ENTITY</u>	<u>OTHER THAN A SMALL ENTITY</u>
FOR:	<u>NO. FILED</u>	<u>NO. EXTRA</u>	<u>RATE</u>	<u>FEE OR RATE FEE</u>
BASIC FEE	XXXXXXXXXX	XXXXXXXXXX	XXXX	\$395 XXXX \$790
TOT. CLAIMS	14-20=-06	* 0	X 11 = \$	0 OR X 22 = \$
INDEP CLAIMS	1-3= -2	* 1	X 41 = \$	0 OR X 82 = \$

Commissioner of Patent and Trademarks
January 19, 1998
Page 2

[0] MULTIPLE CLAIMS PRESENTED + 135= \$ 0 OR + 270= \$
TOTAL \$395 OR TOTAL \$

* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

The Commissioner is hereby authorized to charge any additional filing fees required to Deposit Account No. 500358.


This patent application claims the benefit under 35 USC § 119(e) of the priority date of provisional application Serial No. 60/039,106, filed Feb. 25, 1997.

Please acknowledge receipt of these documents by returning the enclosed self addressed postal card.

Please send all correspondence to the undersigned.

Pursuant to 37 CFR Section 1.10, the undersigned certifies that this communication was deposited with the U.S. Postal Service, "Express Mail Post Office Addressee" service on January 20, 1998, and addressed to the Commissioner of Patents and Trademarks, BOX PATENT APPLICATION, Washington, D.C. 20231. The "Express Mail" mailing label number is EM116 344 284US.

Sincerely yours,



Harold J. Fassnacht
Reg. No. 35,507

Enclosures

cc: Liang Guo w/enclosures
John T. Allen w/o encl.

0900597-012093

**Application for Letters Patent
of the United States of America by -**

**ROBERT M. MORIARTY
1030 Erie Street
Oak Park, Illinois 60302**

**RAJU A. PENMASTA
811 Dunham Lane
Bolingbrook, Illinois 60440**

**LIANG GUO
221 Mountain Drive
Bolingbrook, Illinois 60440**

**MUNAGALA S. RAO
1019 Beninford Lane
Westmont, Illinois 60559**

and

**RAJENDRA G. MEHTA
11721 Springbrook Ct.
Orland Park, Illinois 60462**

For

**1 α -HYDROXYVITAMIN D₅, ITS SYNTHESIS AND
USE IN CANCER PREVENTION AND THERAPY**

09005957-012099

Specification

1 α -Hydroxyvitamin D₅, ITS SYNTHESIS AND USE IN CANCER PREVENTION AND THERAPY

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/039,106 filed February 25, 1997.

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to biologically active vitamin D₅ compounds. More specifically, this invention relates to a series of novel D₅ compounds, including the compound 1 α -Hydroxyvitamin D₅, their synthesis and their use in cancer prevention and therapy.

Description of the Related Art

Vitamin D is a secosteroid and is classified as a hormone within the steroid hormone family. Vitamin D's are differentiated on the basis of side-chain chemical structures into different series, e.g., D₂, D₃, D₄, D₅, and D₆. To date, attention has been focused almost exclusively on the vitamin D₃ series of compounds. In its biological form, vitamin D₃ is inactive until it is metabolized to 1 α ,25-dihydroxyvitamin D₃ [1 α ,25(OH)₂D₃], the natural metabolite. The inactive 24-hydroxy form of the hormone is excreted from the body. The active metabolite 1 α ,25(OH)₂D₃ has been shown to suppress the growth in

vitro of many neoplastic cells, including breast cancer cells. In addition, treatment of colon cancer cells and leukemia cells with $1\alpha,25(\text{OH})_2\text{D}_3$ results in a reduction in the growth rate of these cells.

5 One of the limiting factors in the successful use of vitamin D_3 in cancer prevention or cancer therapy is its calcemic activity, i.e., the potentially fatal build-up of calcium in the body. The concentrations of vitamin D_3 required to suppress growth of neoplastic cells can cause hypercalcemia and death. 10 Therefore, in recent years, numerous analogues of vitamin D have been synthesized that possess reduced calcemic activity without compromising their antiproliferative activity. The differences in structures of these new compounds arise mostly from modifications in the A and D rings and side chain of the vitamin.

15 We have synthesized the novel compound 1α -Hydroxyvitamin D_5 [$1\alpha(\text{OH})\text{D}_5$] and compared its effectiveness as a chemopreventative to the active metabolite of vitamin D_3 . We have also attempted to determine the possible mechanism of such chemopreventative action by studying the expression of vitamin D receptors (VDRs) 20 and transforming growth factor- β (TGF- β) in normal mammary epithelial cells.

Usefulness of 1α -Hydroxyvitamin D_3 : 1α -Hydroxyvitamin D_3 [$1\alpha(OH)D_3$] is useful because it exhibits pharmacological activity in animals. In particular, preliminary studies in mice indicate 1α -Hydroxyvitamin D_3 is useful in preventing development of carcinogen-induced precancerous lesions at non toxic concentrations.

Use of 1α -Hydroxyvitamin D_3 in Cancer Prevention: Results show that the vitamin D_3 analogue $1\alpha(OH)D_3$ inhibits 7,12 dimethylbenz[a]anthracene (DMBA) induced mammary lesions in mammary gland organ culture. This assay has been used to predict possible chemopreventive agents in future clinical trials by the National Cancer Institute. The inhibitions of induction of lesions was accompanied by induction of vitamin D receptors and transforming growth factor $\beta 1$.

1α -Hydroxyvitamin D_3 is less calcemic than a majority of the analogues of vitamin D_3 . This will allow its possible use in prevention of cancer for women at high risk of developing cancer such as women with a family history of cancer or women who may be at a risk of developing disease in the contralateral breast. In addition to breast cancer prevention, the analogue $1\alpha(OH)D_3$ may be employed for prevention of cancers of other sites.

Use of 1α -Hydroxyvitamin D_3 in Cancer Therapy: Our studies showed that $1\alpha(OH)D_3$ inhibited growth of several human breast cancer cell lines, including ZR 75, T47D, MCF10neo, MCF-7, and BCA-4. The agent differentiates the cells making them less effective for forming cancers. Once the cells were

differentiated with the analogue of D₅, they did not grow in athymic mice when transplanted. Similarly, injection of 8 mg of 1 α (OH)D₅ (3 X week/2 months) to athymic mice bearing breast cancer cells inhibited growth of cancer cells in the animals.

5 These results clearly suggest possible use of analogues of D₅ as chemotherapeutic agents or as adjuvants to chemotherapeutic protocol.

BRIEF DESCRIPTION OF THE DRAWINGS

10 The present invention will hereinafter be described in conjunction with the appended drawings.

Figure 1 illustrates the synthesis of 1 α -Hydroxyvitamin D₅ from stigmasterol; and

15 Figure 2 illustrates the various analogues of 1 α -Hydroxyvitamin D₅.

DETAILED DESCRIPTION OF THE DRAWINGS

20 We have synthesized the novel compound 1 α -Hydroxyvitamin D₅ and compared its calcemic activity, cancer prevention efficacy and toxicity to that of the active metabolite of vitamin D₃. We have also attempted to determine the possible mechanism of the chemopreventive activity of 1 α -Hydroxyvitamin D₅ by studying the expression of VDRs and TGF- β 1 in normal mammary epithelial cells.

25 I. SYNTHESIS OF 1 α -Hydroxyvitamin D₅

1 α -Hydroxyvitamin D₅ was prepared by the synthesis outlined

in Figure 1 and described in detail below. Numbers in parentheses refer to numerals in Fig. 1.

Step 1 - Preparation of stigmasterol tosylate (2): To a solution of stigmasterol (1) (50 g, 121.15 mmol) in anhydrous pyridine (400 ml) was added tosyl chloride (46.19 g, 242.3 mmol) under argon. The solution was stirred overnight at room temperature (20 hours) in the dark. The reaction mixture was poured into a 400 mL cold 5% NaHCO₃ solution. The pale crystalline precipitate was filtered, washed with water and air dried to yield 65g (95%) of stigmasterol tosylate (2).

Step 2 - Preparation of stigmasterol methyl ether (3): A suspension of stigmasterol tosylate (2) (64 g, 112.9 mmol) and potassium acetate (70 g, 713.19 mmol) in anhydrous methanol (1500 mL) was refluxed for 4.5 h under argon atmosphere. The methanol was evaporated in vacuo, and then ether (2 L) was added, washed with water (500 mL), 5% NaHCO₃ (2 X 400 mL) and brine (400 mL) and dried (MgSO₄). The solvent was evaporated in vacuo to afford 47 g (92%) of stigmasterol methyl ether (3) as a pale yellow viscous liquid.

Step 3 - Preparation of sitosterol methyl ether (4): A solution of stigmasterol methyl ether (3) (10 g, 23.43 mmol) in ethyl acetate (250 mL) and 10% Pd-C (3 g) was shaken in Parr hydrogen apparatus for 4 h (30-40 psi). The Pd-C was filtered through Celite. The solvent was removed in vacuo to afford sitosterol methyl ether (4) in quantitative yield.

Step 4 - Preparation of Sitosterol acetate (5): To a

solution of sitosterol methyl ether (4) (50 g, 116.62 mmol) in glacial acetic acid (1 L) was added zinc acetate (65 g, 354.3 mmol). The reaction mixture was refluxed for 6 h, cooled, then 1.5 L of water was added. The resulting white precipitate was filtered, washed with water and air dried. Recrystallization in ether-methanol afforded 42 g (79%) of sitosterol acetate (5) as a white crystalline solid.

Step 5 - Preparation of 7-Dehydrositosterol acetate (6): A suspension of sitosterol acetate (5) (10 g, 21.89 mmol), anhydrous NaHCO_3 (9.19 G, 109.45 mmol) and dibromantin in heptane (250 mL) was refluxed for 2 h under argon atmosphere. The reaction mixture was cooled to room temperature and filtered, and then the solvent was removed *in vacuo*. To the reaction flask, THF (50 mL) was added followed by tetrabutylammonium bromide (0.65 g, 2.02 mmol). The solution was stirred at room temperature for 30 minutes under argon atmosphere. To this reaction mixture tetrabutylammonium fluoride (112 mL, 1 M solution in THF) was added and followed by s-collidine (5 mL). Then the reaction mixture was stirred at room temperature for 20 h. The reaction mixture was diluted with ether (1.5 L), then water (600 mL) was added. The crude reaction mixture was transferred to a separating funnel, the water layer was removed, the organic layer was washed with water (500 mL), 1 N HCl (2 X 600 mL), water (600 mL), then brine (500 mL). The organic layer was dried (MgSO_4) and concentrated *in vacuo* to afford a dark brown viscous liquid. The crude reaction mixture was purified by

15

20

25

column chromatography (silica gel, ethyl acetate-hexane 1:9 mixture as eluent) to afford 6.5 g, (75%) 7-dehydrositosterol acetate (6) as a pale brown viscous liquid.

Step 6 - Preparation of 7-Dehydrositosterol (7): To a solution of 7-dehydrositosterol acetate (6) (2.5 g, 5.5 mmol) in dry ether (200 mL) was added lithium aluminum hydride (2.09 g, 55.0 mmol). The reaction mixture was stirred at room temperature for 2 h, then cooled with an ice-water bath and the excess water (5 mL). After 30 minutes, ether (100 mL) was added and filtered. The cake was washed with ether (2 X 100 mL) and the combined organic extracts were dried (MgSO_4), filtered and concentrated *in vacuo* to afford 7-dehydrositosterol (7) in quantitative yield.

Step 7 - Preparation of Previtamin D_5 (8): 7-Dehydrositosterol (7) (1.5 g, 3.63 mmol) was dissolved in anhydrous ether (630 mL) and benzene (210 mL) and irradiated with stirring under argon in a water cooled quartz immersion well using a Hanovia medium-pressure mercury vapor lamp for 2 h. The reaction mixture was concentrated *in vacuo* to afford the crude previtamin D_5 as a pale brown viscous liquid. The crude reaction mixture was used without purification in the next step.

Step 8 - Preparation of Vitamin D_5 (9): 7-Dehydrositosterol (7) (1.5 g, 3.63 mmol) in ethanol (200 mL) was heated at 60°C for 4 h. The reaction was monitored by TLC. The solution was concentrated *in vacuo* and the crude vitamin D_5 was purified on a silica gel column using 20% ethyl acetate in hexane to yield 600 mg (40%) of Vitamin D_5 (9).

Step 9 - Preparation of Vitamin D₅ tosylate (10): To a solution of Vitamin D₅ (9) (1.6 g, 3.88 mmol) in dry pyridine (20 mL) was added p-toluenesulfonyl chloride (2.22 g, 11.63 mmol). The reaction mixture was stirred under argon for 20 h at room temperature then poured into a cold saturated NaHCO₃ solution (100 mL). The mixture was extracted with ether (3 X 200 mL) and the combined organic extracts were washed with 5% HCl (2 X 200 mL), saturated sodium bicarbonate (2 X 200 mL) and brine (200 mL), dried (MgSO₄) and concentrated *in vacuo* to yield 2 g (98%) of Vitamin D₅ tosylate (10) as a brown viscous liquid.

Step 10 - Preparation of 3,5-Cyclovitamin D₅ (11): To a solution of Vitamin D₅ tosylate (10) (2 g, 3.53 mmol) in anhydrous methanol (250 mL) was added sodium bicarbonate (18 g, 214.26 mmol). The reaction mixture was heated under reflux for 8 h, then cooled and concentrated *in vacuo*. Water (300 mL) was added to the residue and the mixture was extracted with ether (2 X 300 mL). The combined organic extracts were washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo* to yield 1.18 g (78%) of 3,5-cyclovitamin D₅ (11) as an oil.

Step 11 - Preparation of 1 α -Hydroxy-3,5-Cyclovitamin D₅ (12): To a suspension of selenium dioxide (222 mg, 2 mmol) in dry methylene chloride (160 mL) was added t-butyl hydroperoxide (2.9 mL, 8 mmol, 3 M solution in toluene) under argon. The reaction mixture was stirred under argon at room temperature for 3 h, then dry pyridine (0.3 mL) was added followed by a solution of 3,5-cyclovitamin D₅ (11) (1.5 g, 3.52 mmol) in dry methylene

chloride (50 mL). The reaction mixture was stirred at room temperature for 30 minutes, then 10% NaOH solution (60 mL) was added and the mixture was extracted with ether (3 X 250 mL). The combined organic extracts were washed with 10% NaOH solution (2 X 200 mL), water (2 X 200 mL) and brine (200 mL) and dried (MgSO₄) and concentrated *in vacuo*. The crude residue was purified by silica gel column chromatography using 20% ethyl acetate in hexane to yield 545 mg (35%) of 1 α -hydroxy-3,5-cyclovitamin D₅ (12) as an oil.

Step 12 - Preparation of 1 α -Hydroxyvitamin D₅ (13): A solution of 1 α -hydroxy-3,5-cyclovitamin D₅ (12) (360 mg, 0.813 mmol) in DMSO (4 mL) and acetic acid (3.5 mL) was stirred and heated at 54-55°C for 1 h under argon. The reaction mixture was poured into crushed ice (100 g), saturated NaHCO₃ (80 mL) was added to it, and the mixture was extracted with ether (3 X 150 mL). The combined organic extracts were washed with saturated NaHCO₃ solution (2 X 200 mL), water (2 X 150 mL) and brine (200 mL), dried (MgSO₄) and concentrated *in vacuo*, to yield 331 mg (95%) of a mixture of 1 α -Hydroxyvitamin D₅ (13) and its 5,6-*trans* isomer (14).

Step 13 - Purification of 1 α -Hydroxyvitamin D₅ (13): The crude reaction mixture of 1 α -Hydroxyvitamin D₅ (13) and its 5,6-*trans* isomer (14) (320 mg, 0.75 mmol) was dissolved in ethyl acetate (70 mL) and then maleic anhydride (73 mg, 0.75 mmol) was added. The reaction mixture was stirred at 35°C for 24 h under argon. The solution was concentrated *in vacuo*. The crude

residue was purified on a silica gel column using 50 % ethyl acetate in hexane to yield 150 mg (47%) of 1 α -Hydroxyvitamin D₅ as a white solid. The compound (13) was crystallized from methylformate as white needles and further purified by HPLC (4.6 X 26 cm, C-18 column, CH₃ CN:H₂O 9:1) to afford 80 mg of 1 α -Hydroxyvitamin D₅ (13), > 99% purity: mp 145-146°C; IR (KBr): 3416 and 1638 cm⁻¹; UV (CH₃OH): λ max ^{265 nm} (ϵ 18,913); ¹H NMR (CDCl₃, 400 MHz) δ 0.54 (s, 3H, 18-CH₃, 0.72-0.98 (m, 9H), 0.92 (d, 3H, J=6Hz, C21-CH₃), 4.24 (m, 1H, 1-H), 4.43 (m, 1H, 3-H), 5.0 (m, sharp, 1H, 19 (E)-H), 5.33 (m, sharp, 1H, 19 (Z)-H), 6.01 (d, 1H, J=11.3 Hz, 7-H), 6.38 (d, 1H, J=11.3 Hz, 6-H); MS (CI) m/e 429 (M⁺, 37%).

Thus the present invention provides the compound 1 α -Hydroxyvitamin D₅ indicated by numeral (13) in Figures 1 and 2, and compounds (13a) - (13e) in Figure 2 obtained from 1 α -Hydroxyvitamin D₅ using literature procedures. In addition to the above compounds, the invention also provides compounds with stereochemistry at carbon centers C₁ (R or S), C₃ (R or S), C₂₀ (R or S) and C₂₄ (R or S) in Figure 2.

II. COMPARISON OF CALCEMIC ACTIVITY, CHEMOPREVENTIVE ACTIVITY,
AND TOXICITY OF 1α -Hydroxyvitamin D₃ AND $1\alpha,25$ -
DIHYDROVITAMIN D₃

A. Experimental Equipment and Methods

1. High-Pressure Liquid Chromatography (HPLC)
Analysis of Vitamin D Analogues

The vitamin D₃ and D₅ analogues were dissolved in acetonitrile at a final concentration of 0.2 mg/mL. Aliquots (10 μ L) were injected on a Suplex PKB-100 HPLC column at ambient temperature. The HPLC was carried out with the use of an Hitachi L-6000 pump, an L-4200 UV-VIS detector, and an AS-2000 autosampler (Hitachi Instruments, Inc., Naperville, IL). The vitamin D analogues were eluted with the mobile phase of acetonitrile-methanol-water (52:30:18, vol/vol) with the flow rate at 1 mL/minute, and the elution profile was monitored at 254 nm.

Both 1α -Hydroxyvitamin D₅ and $1\alpha,25$ -dihydroxyvitamin D₃ analogues exhibited about 98% purity. Stability studies have suggested that both can be stored in powder form for a year at 20°C, whereas in solution they are stable for one month at the same temperature.

2. Measurement Of Calcemic Activity In Rats
Administered Vitamin D Analogues

Three-week-old Sprague-Dawley male rats were obtained from the Holtzman Laboratory, Madison, WI. Up to three rats were housed together in a polycarbonate cage. The animal cages were kept under yellow light. The rats (eight to 10 per group per concentration of both vitamin D analogues used) were fed a

vitamin D-free diet containing 0.47 g/100 g calcium and 0.3 g/100 g phosphorus. After the rats had consumed this diet for 3 weeks, their plasma calcium levels were measured. Rats exhibiting plasma calcium levels of less than 6.0 mg/dL were considered to be vitamin D deficient. Such rats were administered appropriate vitamin D analogues intragastrically for 14 days. At the end of this period, the plasma calcium levels were again measured.

3. Induction Of Preneoplastic Lesions In Mammary Glands And Their Prevention By Vitamin D₃ and D₅ Analogues

Young, virgin BALB/c female mice, 3-4 weeks of age, were obtained from Charles River Laboratories, Wilmington, MA. The mice were pretreated for 9 days with 17 β -estradiol (1 μ g in 0.1 mL saline per animal) and progesterone (1 mg in 0.1 mL saline per animal). They were then killed by cervical dislocation, and the thoracic pair of mammary glands was dissected out on silk rafts and incubated for 10 days in Waymouth MB752 medium (Life Technologies, Inc. [GIBCO BRL], Gaithersburg, MD) containing the following growth-promoting hormones: insulin (5 μ g/mL), prolactin (5 μ g/mL), aldosterone (1 μ g/mL), and hydrocortisone (1 μ g/mL).

The carcinogen 7,12-dimethylbenz[a]anthracene (DMBA) at a dose of 2 μ g/mL was added to the medium on day 3 for 24 hours to induce mammary lesions. The DMBA-containing medium was then removed, and the mammary glands were incubated for an additional 14 days with medium containing only insulin. This procedure allowed the normal glands to undergo structural regression in which all the normal alveolar structures were disintegrated.

However, the alveolar lesions in the carcinogen-treated glands behaved differently. They had acquired altered hormone responsiveness, and these structures did not regress. These structures were termed "mammary lesions."

5 The vitamin D analogues (ranging in concentration from 0.01 μ M to 10.0 μ M) were included in the medium during the first 10 days of the in vitro culture to determine if they lowered the incidence of mammary lesion formation. Throughout the culture period, the glands were maintained at 37°C in an environment of
10 95% air and 5% CO₂.

At the end of the culture period, the glands were fixed in formalin, stained in alum-carmin solution, and evaluated for the presence or absence of mammary lesions. All hormones and chemicals were purchased from the Sigma Chemical Co., St. Louis,
15 MO.

4. Immunohistochemistry Of VDRs And TGF- β 1

Normal mouse mammary glands were dissected and incubated with growth-promoting hormones either alone or in the presence of
20 vitamin D analogues for only 3 days. In this experiment, the glands were not exposed to DMBA (see protocol described in the previous section). Instead, the glands were fixed in buffered formalin, and 5- μ m-thick sections were prepared for histopathologic evaluations. The sections were mounted on
25 adhesive-coated slides (Superfast: Fisher Scientific Co., Itasca, IL), dried at 60°C for 1 hour, deparaffinized in xylene,

dehydrated in a series of alcohol, and finally washed with phosphate-buffered saline (PBS).

To block the nonspecific antibody reactions, we treated the tissue sections with 5% dried skim milk for 10 minutes and then incubated them with primary mouse antibody (either against VDR or against TGF- β 1, both obtained from BioGenex Laboratories, San Ramon, CA) overnight at 0-4°C. The tissues were rinsed in PBS and incubated with biotinylated rabbit anti-mouse antibody (Dako Corp., Carpinteria, CA.) for 10 minutes; the remaining steps were followed according to the manufacturer-specified protocol; i.e., the reaction was stopped by rinsing the sections with PBS, which was followed by a 10 minute incubation with peroxidase-conjugated streptavidin, three 10-minute rinses with PBS, and a 5-minute incubation in a substrate, 3,3'-diaminobenzidine tetrachloride.

The tissues were counterstained with hematoxylin-eosin, dehydrated through graded series of alcohol and xylene, and finally mounted in Permount (Fisher Scientific Co.). Slides were evaluated for the presence or absence of the VDR or TGF- β 1 and for the intensity of staining in the positively stained samples.

5. Statistical analysis

Statistical significance of the results was determined by the chi-squared test. All reported *P* values were obtained from two-sided tests.

B. Experimental Results

1. Calcemic Activity:

One of the primary reasons to synthesize new vitamin D agents is to prepare analogues that have reduced calcemic activity compared with that of $1\alpha,25(\text{OH})_2\text{D}_3$, but without compromising the antiproliferative activity. We measured the calcemic activity of both 1α -Hydroxyvitamin D_5 and $1\alpha,25$ -dihydroxyvitamin D_3 .

As shown in Table 1, the vehicle-treated control rats showed a plasma calcium concentration of 5.4 ± 0.28 mg/dL (mean \pm standard deviation). When the rats were treated with the vitamin D analogues at a dose of 0.042 $\mu\text{g}/\text{kg}$ per day, the following plasma calcium concentrations were observed: 6.0 ± 0.63 mg/dL for $1\alpha(\text{OH})\text{D}_5$ -treated rats (an 11% increase over that of the vehicle-treated control group; $P = .121$, i.e., not statistically significant when compared with that of the control group) and 8.1 ± 1.2 mg/dL for $1\alpha,25(\text{OH})_2\text{D}_3$ -treated rats (a 50% increase over that of the control group; $P = .002$, i.e., statistically significant difference when compared with that of the control group). At a higher concentration of vitamin D analogues (0.25 $\mu\text{g}/\text{kg}$ per day), $1\alpha(\text{OH})\text{D}_5$ treatment resulted in a plasma calcium concentration of 7.9 ± 1.5 mg/dL compared with 10.1 ± 1.8 mg/dL for $1\alpha,25(\text{OH})_2\text{D}_3$ treatment. Although both analogues at this concentration increased the plasma calcium levels in comparison with those in vehicle-treated control rats, these results showed that $1\alpha(\text{OH})\text{D}_5$ has overall lower calcemic effects than

$1\alpha,25(\text{OH})_2\text{D}_3$.

5 $1\alpha,25(\text{OH})_2\text{D}_3$ treatment resulted in an 87% increase in the plasma calcium level in rats when compared with the vehicle-treated rats. On the other hand, in animals treated with a higher concentration of $1\alpha(\text{OH})\text{D}_5$, there was only a 50% increase in the plasma calcium concentration compared with that in the control animals. These results suggest that $1\alpha(\text{OH})\text{D}_5$ is much less calcemic than $1\alpha,25(\text{OH})_2\text{D}_3$.

Table 1

Effects of vitamin D analogues on plasma calcium levels
in vitamin D-deficient rats

Treatment ¹	No. of rats	Dose, $\mu\text{g/kg/day}$	Plasma calcium, mg/dL^2	P (two-sided test)
None	8	0.0	5.4 ± 0.28	
$1\alpha(\text{OH})\text{D}_5$	8	0.042	6.0 ± 0.63	.121
	10	0.25	7.9 ± 1.5	.002
$1\alpha, 25(\text{OH})_2\text{D}_3$	8	0.042	8.1 ± 1.2	.001
	10	0.25	10.1 ± 1.8	<.0001

¹ $1\alpha(\text{OH})\text{D}_5$ = 1α -Hydroxyvitamin D_5 ; $1\alpha, 25(\text{OH})_2\text{D}_3$ = $1\alpha, 25$ -dihydroxyvitamin D_3 .

² Values = means \pm standard deviation.

2. Efficacy of Cancer Prevention

Traditionally, the effectiveness of a variety of chemopreventive agents has been evaluated by organ culture of the mouse mammary gland. In organ culture, mammary glands from mice respond to a short stimulation with a carcinogen in the presence of appropriate hormones by developing preneoplastic lesions. When implanted in syngeneic hosts, mammary cells prepared from these lesions give rise to adenocarcinomas. Effective chemopreventive agents (e.g., certain retinoids, selenium, oltipraz, and limonene) inhibit the formation of these lesions. The relative activity of chemopreventive *in vitro* correlates well with their activity in *in vivo* carcinogenesis experiments. Using this traditional model system, we have evaluated the efficacy of 1α -Hydroxyvitamin D₅ [$1\alpha(\text{OH})\text{D}_5$] in preventing 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary lesion formation in a mouse mammary gland organ culture model.

To evaluate the efficacy of the newly synthesized vitamin D₅ analogue in preventing mammary lesion formation, we incubated 15 mammary glands per group (135 glands in total) from BALB/c mice with appropriate hormones and exposed the glands to DMBA on day 3 for 24 hours (see "Experimental Equipment and Methods" section). The mammary glands were incubated for 10 days with the vitamin D analogues in concentrations ranging from 0.01 μM to 10.0 μM . The incidence of mammary lesions was calculated for each group and was reported as the ratio of the number of mammary glands showing lesions to the total number of mammary glands at risk.

Table 2 shows the incidence of mammary lesions in various groups treated with vitamin D analogues. In the vitamin D₅-treated group there was a dose-related decrease in the number of glands exhibiting lesions. In the group treated with vitamin D₃, only two of 14 glands developed lesions at a concentration of 0.01 μ M. At higher concentrations of this analogue, no mammary lesions were observed.

We calculated the percent inhibition of formation of lesions in each treatment group by comparing the incidence of lesions between the control group and the treatment group. At a concentration of 10.0 μ M, both 1 α (OH)D₅ and 1 α ,25(OH)₂D₃ inhibited the formation of mammary lesions by 100%.

At a concentration of 0.01 μ M, the vitamin D₃ analogue inhibited mammary alveolar lesion formation by 76%; incubation of glands with concentrations of 0.1 μ M and higher showed 100% inhibition. In contrast, the vitamin D₅ analogue inhibited the lesion formation in a dose-dependent manner, reaching 100% inhibition at a concentration of 10.0 μ M.

Table 2

Effects of vitamin D analogues on incidence
of 7,12 dimethylbenz[a]anthracene-induced lesions
in BALB/c mouse mammary glands in organ culture

Concentration (μ M)	1 α -Hydroxyvitamin D ₃			1,25 α -dihydroxyvitamin D ₃		
	No. of glands with lesions/ total No. of glands treated	% inci- dence	P (two sided test)	No. of glands with lesions/ total No. of glands treated	% inci- dence	P (two sided test)
None	9/15	60.0		9/15	60.0	
0.01	6/16	37.5	.21	2/14	14.3	.011
0.1	4/16	25.0	.048	0/15	0.0	.003
1.0	2/14	14.3	.011	0/15	0.0	.003
10.0	0/15	0.0	.003	0/15	0.0	.003

3. Toxicity

To determine the effects of vitamin D analogues on the structural differentiation as well as their toxic effects on mammary glands, we incubated mammary glands with growth-promoting hormones for 3 days either alone or in the presence of 0.1 μ M or 1.0 μ M vitamin D analogues. The control mammary gland structure was represented by normal alveolar and ductal structures.

$1\alpha,25(\text{OH})_2\text{D}_3$ at a concentration of 0.1 μ M did not show toxicity. Mammary glands displayed normal ductal and alveolar structures. At a concentration of 1.0 μ M, vitamin D_3 analogue treatment resulted in disintegration of ducts and structural toxicity to the glands.

In contrast, treatment with the vitamin D_5 analogue at a concentration of 1.0 μ M retained the healthy structural characteristics seen in the untreated glands. In fact, some secretion was obvious in the lumen of the ducts.

In summary, $1\alpha,25(\text{OH})_2\text{D}_3$ was toxic to the glands at concentrations of 1.0 μ M or higher. Treatment of mammary glands with $1\alpha(\text{OH})\text{D}_5$ did not result in any toxicity to the glands.

4. Mechanism of the Vitamin D Chemopreventive Activity

The mechanism of the vitamin D chemopreventive action is not completely understood. Nuclear vitamin D receptor (VDR) protein binding to $1\alpha,25(\text{OH})_2\text{D}_3$ has been identified and is shown to be present in a variety of tissues, including normal mammary glands and mammary tumors, as well as in breast cancer cells. In the

cytosol of target organs or cells, [³H]1,25(OH)₂D₃ binds specifically to receptors with a dissociation constant (K_d) ranging from 1 x 10⁻¹⁰ M to 6 x 10⁻¹⁰ M. An increased nuclear VDR concentration has been found to be associated with an enhanced expression of messenger RNA for vitamin D₃ receptors. The VDR gene has been cloned, and the molecular structure of the receptor protein has been determined. The results have demonstrated that the VDR belongs to the steroid-, thyroid-, and retinoid-receptor superfamily. All of these receptors act as ligand-dependent transcription factors that bind to specific DNA sequences. Two classes of response elements have been identified that are activated either by VDR alone or by heterodimers of VDRs and retinoid X receptor (RXR) alpha.

In recent years, considerable attention has been given to the regulation of cell growth by autocrine antiproliferative factors. Inhibition of cancer cell growth is often related to enhanced production of transforming growth factor- β (TGF- β). TGF- β is further subclassified into the following three isoforms of polypeptides: TGF- β 1, TGF- β 2, and TGF- β 3. These isoforms are present in mammalian cells, including breast cancer cells. The isoforms of TGF- β are regulated differentially by steroid and protein hormones. In one report, a hexafluoro analogue of vitamin D₃, 1 α ,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), induced expression in HL-60 human leukemia cells of TGF- β 1 and its type 2 receptors. These results suggest a possible interaction between the function

of VDR and TGF- β regulation. Induction of TGF- β , however, is often reported only in transformed cells. Although the growth-inhibitory role of TGF- β has been reported in the normal mammary gland, induction of TGF- β in response to chemopreventive agents in this tissue has not been reported previously.

Since the role of chemopreventive agents (including vitamin D₃ and vitamin D₅) on the induction of TGF- β in normal mammary epithelial cells has not been studied, the histologic sections of normal mammary glands treated with either only hormones (insulin, progesterone, aldosterone, and hydrocortisone) or hormones plus vitamin D analogues were processed immunohistochemically to investigate the effects of vitamin D analogues on the induction and localization of VDRs and TGF- β 1. VDRs were localized in the nuclei of mammary epithelial cells. There was no selective localization of VDRs in ductal or alveolar cells. Treatment with either 1.0 μ M 1 α (OH)D₅ or 0.1 μ M 1 α ,25(OH)₂D₃ induced expression of VDRs detectable in the nuclei of both ductal and alveolar cells. This induction was dependent on the concentration of the analogue; VDR induction was much less at the lower concentration of the vitamin D₅ analogue. For the vitamin D₃ analogue, intense staining was evident at a lower concentration (0.1 μ M). However, at a concentration of 1.0 μ M, reduced or absent staining was observed as a result of apparent toxicity.

The effects of the vitamin D analogues on the induction of TGF- β 1 were also evaluated. We studied tissue sections from the mammary glands treated with the vitamin D analogues or those from

untreated control glands for the induction of TGF- β 1. We found extensive induction of TGF- β 1 in the cytoplasm of mammary epithelial cells. Again, the pattern of intensity was comparable to that of induction of VDR. The extent of induction of TGF- β 1 after treatment with the vitamin D₅ analogue at a concentration of 1.0 μ M was similar to that observed with the vitamin D₃ analogue at a concentration of 0.1 μ M. However, at a concentration of 1.0 μ M of the vitamin D₃ analogue, TGF- β 1 expression was much reduced as a result of toxicity. These results indicate that the vitamin D₅ analogue is considerably less toxic than the vitamin D₃ analogue. Moreover, they indicate that this remarkable induction of TGF- β 1 in mammary epithelial cells by the vitamin D₅ analogue may be of importance in cancer chemoprevention.

Thus we have synthesized a novel vitamin D₅ compound and compared its calcemic activity, cancer prevention efficacy, and toxicity to that of vitamin D₃. We have found that 1 α -Hydroxyvitamin D₅, while not completely devoid of calcemic activity, exhibited lower toxicity than 1 α ,25-dihydroxyvitamin D₃. The present invention represents a first step toward the long-term goal of investigating the efficacy of chemoprevention by and the mechanism(s) of action of analogues of the vitamin D₅ series of compounds. Reduced calcemic activity and lack of toxicity make 1 α -Hydroxyvitamin D₅ an attractive candidate for further in vivo chemoprevention studies.

CIVILIAN POPULATION	
1970	100.0
1980	100.0
1990	100.0
2000	100.0
2010	100.0
2020	100.0
2030	100.0
2040	100.0
2050	100.0
2060	100.0
2070	100.0
2080	100.0
2090	100.0
2100	100.0
2110	100.0
2120	100.0
2130	100.0
2140	100.0
2150	100.0
2160	100.0
2170	100.0
2180	100.0
2190	100.0
2200	100.0
2210	100.0
2220	100.0
2230	100.0
2240	100.0
2250	100.0
2260	100.0
2270	100.0
2280	100.0
2290	100.0
2300	100.0
2310	100.0
2320	100.0
2330	100.0
2340	100.0
2350	100.0
2360	100.0
2370	100.0
2380	100.0
2390	100.0
2400	100.0
2410	100.0
2420	100.0
2430	100.0
2440	100.0
2450	100.0
2460	100.0
2470	100.0
2480	100.0
2490	100.0
2500	100.0
2510	100.0
2520	100.0
2530	100.0
2540	100.0
2550	100.0
2560	100.0
2570	100.0
2580	100.0
2590	100.0
2600	100.0
2610	100.0
2620	100.0
2630	100.0
2640	100.0
2650	100.0
2660	100.0
2670	100.0
2680	100.0
2690	100.0
2700	100.0
2710	100.0
2720	100.0
2730	100.0
2740	100.0
2750	100.0
2760	100.0
2770	100.0
2780	100.0
2790	100.0
2800	100.0
2810	100.0
2820	100.0
2830	100.0
2840	100.0
2850	100.0
2860	100.0
2870	100.0
2880	100.0
2890	100.0
2900	100.0
2910	100.0
2920	100.0
2930	100.0
2940	100.0
2950	100.0
2960	100.0
2970	100.0
2980	100.0
2990	100.0
3000	100.0
3010	100.0
3020	100.0
3030	100.0
3040	100.0
3050	100.0
3060	100.0
3070	100.0
3080	100.0
3090	100.0
3100	100.0
3110	100.0
3120	100.0
3130	100.0
3140	100.0
3150	100.0
3160	100.0
3170	100.0
3180	100.0
3190	100.0
3200	100.0
3210	100.0
3220	100.0
3230	100.0
3240	100.0
3250	100.0
3260	100.0
3270	100.0
3280	100.0
3290	100.0
3300	100.0
3310	100.0
3320	100.0
3330	100.0
3340	100.0
3350	100.0
3360	100.0
3370	100.0
3380	100.0
3390	100.0
3400	100.0
3410	100.0

I

-
- The chemical structure shows a complex molecule. It features a bicyclic system (two fused six-membered rings) connected via a vinyl group to a cyclohexane ring. The cyclohexane ring has two hydroxyl groups (HO) and a methyl group. A side chain is attached to the bicyclic system, containing a chiral center with substituents R1, R2, R3, and R4.

R1 is hydrogen;
R2 is -CH₃;
R3 is -CH₃; and
R4 is hydrogen.

- 26

- a. R1 is hydrogen;
- b. R2 is -OH;
- c. R3 is -CF₃; and
- d. R4 is -CF₃.

6. A compound of formula I wherein:

- a. R1 is hydrogen;
- b. R2 is hydrogen;
- c. R3 is -CH₂OH; and
- d. R4 is -CH₃.

7. A method of synthesizing the compound of formula I comprising the steps of:

- (1) adding tosyl chloride to stigmasterol to make stigmasterol tosylate;
- (2) refluxing the stigmasterol tosylate with potassium acetate in methanol to prepare stigmasterol methyl ether;
- (3) shaking the stigmasterol methyl ether in ethyl acetate and Pd-C to make sitosterol methyl ether;
- (4) refluxing zinc acetate added to a solution of sitosterol methyl ether in acetic acid to make sitosterol acetate;
- (5) refluxing a suspension of sitosterol acetate, anhydrous NaHCO₃ and dibromantin in heptane; adding THF and tetrabutyl ammonium bromide and tetrabutyl ammonium fluoride and N-collidine to make 7-dehydrositosterol acetate;
- (6) adding lithium aluminum hydride to the 7-dehydrositosterol to make 7-dehydrositosterol;
- (7) dissolving the 7-dehydrositosterol in anhydrous

ether and benzene and irradiating to make previtamin D₅;

- (8) heating a solution of previtamin D₅ in ethanol to make crude vitamin D₅;
- (9) adding p-toluene sulfonyl chloride to a solution of vitamin D₅ in pyridine to make vitamin D₅ tosylate;
- (10) adding sodium bicarbonate to a solution to a solution of vitamin D₅ tosylate in methanol to make 3,5 cyclovitamin D₅;
- (11) adding t-butyl hydroperoxide to a suspension of selenium dioxide in dry methylene chloride and adding a solution of 3,5 cyclovitamin D₅ in dry methylene chloride to make 1 α -Hydroxyvitamin-3,5 cyclovitamin D₅;
- (12) stirring and heating a solution of 1 α -hydroxy 3,5-cyclovitamin D₅ in DMSO and acetic acid to make a mixture of 1 α -Hydroxyvitamin D₅ and its 5,6-trans isomer; and
- (13) dissolving the mixture of 1 α -Hydroxyvitamin D₅ and its 5,6-trans isomer in ethyl acetate and then maleic anhydride, purifying and crystallizing to make 1 α -Hydroxyvitamin D₅.


8. A method of preventing the development of carcinogen-induced precancerous lesions which comprises

administering a therapeutically effective amount of the compound of claim 1 to an individual at risk of developing cancer.

9. A method of treating cancer which comprises administering a therapeutically effective amount of the compound of claim 1 to an individual in need of such treatment.
10. The compound of claim 2 with R or S stereochemistry at carbon centers C₁, C₃, C₂₀ and C₂₄.
11. The compound of claim 3 with R or S stereochemistry at carbon centers C₁, C₃, C₂₀ and C₂₄.
12. The compound of claim 4 with R or S stereochemistry at carbon centers C₁, C₃, C₂₀ and C₂₄.
13. The compound of claim 5 with R or S stereochemistry at carbon centers C₁, C₃, C₂₀ and C₂₄.
14. The compound of claim 6 with R or S stereochemistry at carbon centers C₁, C₃, C₂₀ and C₂₄.

ABSTRACT OF THE DISCLOSURE

A compound of formula I:



I

wherein R1 is hydrogen, R2 is -CH₃, R3 is -CH₃, and R4 is hydrogen, useful in cancer prevention and therapy.

Preparation of 1- α -hydroxy vitamin D₅ from Stigmasterol




Figure 1




Figure 1 (cont.)





Figure 1 (cont.)

Figure 2



13

13: $R_1=H$; $R_2=CH_3$; $R_3=CH_3$; $R_4=H$

13a: $R_1=H$; $R_2=OH$; $R_3=R_4=CH_3$

13b: $R_1=OH$; $R_2=H$; $R_3=R_4=CH_3$

13c: $R_1=OH$; $R_2=OH$; $R_3=R_4=CH_3$

13d: $R_1=H$; $R_2=OH$; $R_3=R_4=CF_3$

13e: $R_1=H$; $R_2=H$; $R_3=CH_2OH$; $R_4=CH_3$

1. Personal information	
1.1 Name	1.2 Age
1.3 Sex	1.4 Marital status
1.5 Education	1.6 Occupation
1.7 Income	1.8 Health status
1.9 Living arrangement	1.10 Social support
1.11 Stress level	1.12 Coping strategy
1.13 Personality	1.14 Attitude
1.15 Self-efficacy	1.16 Resilience
1.17 Optimism	1.18 Hope
1.19 Life satisfaction	1.20 Well-being
1.21 Quality of life	1.22 Mental health
1.23 Physical health	1.24 Emotional health
1.25 Behavioral health	1.26 Cognitive health
1.27 Social health	1.28 Spiritual health
1.29 Environmental health	1.30 Overall health
1.31 Health status	1.32 Health care
1.33 Health insurance	1.34 Health expenditure
1.35 Health equity	1.36 Health justice
1.37 Health system	1.38 Health policy
1.39 Health governance	1.40 Health leadership
1.41 Health innovation	1.42 Health research
1.43 Health evidence	1.44 Health practice
1.45 Health impact	1.46 Health outcome
1.47 Health effect	1.48 Health benefit
1.49 Health value	1.50 Health cost
1.51 Health return	1.52 Health investment
1.53 Health risk	1.54 Health hazard
1.55 Health threat	1.56 Health danger
1.57 Health problem	1.58 Health issue
1.59 Health concern	1.60 Health challenge
1.61 Health obstacle	1.62 Health barrier
1.63 Health constraint	1.64 Health limitation
1.65 Health restriction	1.66 Health restriction
1.67 Health limitation	1.68 Health restriction
1.69 Health barrier	1.70 Health obstacle
1.71 Health challenge	1.72 Health issue
1.73 Health concern	1.74 Health problem
1.75 Health threat	1.76 Health hazard
1.77 Health risk	1.78 Health value
1.79 Health return	1.80 Health investment
1.81 Health cost	1.82 Health benefit
1.83 Health effect	1.84 Health impact
1.85 Health outcome	1.86 Health practice
1.87 Health research	1.88 Health evidence
1.89 Health innovation	1.90 Health governance
1.91 Health leadership	1.92 Health policy
1.93 Health system	1.94 Health equity
1.95 Health justice	1.96 Health care
1.97 Health expenditure	1.98 Health insurance
1.99 Health status	1.100 Health well-being

As the below-named inventors, we hereby declare that:

We believe we are the original, first and only inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled

the specification of which is attached hereto.

We hereby state that we have reviewed and understand the content of the above-identified specification, including the claims and any amendments thereto.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, section 1.56(a).

We hereby claim foreign priority benefits under Title 35, United States Code, section 119, of any foreign applications for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Applications

Priority Claimed

(none)

We hereby claim the benefit under Title 35, United States Code, section 120 of any United States application listed below, and insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, section 112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulation, section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

App. Serial No.

Filing Date

Status

60/039,106

02/25/97

Provisional

POWER OF ATTORNEY

As named inventors, we hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Harold J. Fassnacht, Reg. No. 35,507
George E. Bullwinkel, Reg. No. 24,585
BULLWINKEL PARTNERS, LTD.
19 South LaSalle Street - Suite 1300
Chicago, Illinois 60603-1493
Tel. (312) 201-0777

FIRST INVENTOR:

Full Name: Robert M. Moriarty

Residence
address: 1030 Erie Street
Oak Park, IL 60302

Citizen of: U.S.A.

Post Office
address: Same as above.

SECOND INVENTOR:

Full Name: Raju A. Penmasta

Residence
address: 811 Dunham Lane
Bolingbrook, IL 60440

Citizen of: India (Permanent resident USA)

Post Office
address: Same as above.

THIRD INVENTOR:

Full Name: Liang Guo

Residence
address: 221 Mountain Drive
Bolingbrook, IL 60440

Citizen of: U.S.A.

Post Office
address: Same as above.

FOURTH INVENTOR:

Full Name: Munagala S. Rao
Residence
address: 1019 Beninford Lane
Westmont, IL 60559
Citizen of: India (Permanent resident USA)
Post Office
address: Same as above.

FIFTH INVENTOR:

Full Name: Rajendra G. Mehta
Residence
address: 11721 Springbrook Ct.
Orland Park, IL 60462
Citizen of: U.S.A.
Post Office
address: Same as above.

DECLARATION: We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Robert M. Morley
(Signature of Inventor)
1/11/98
(Date)

Rajendra Mehta
(Signature of Inventor)
1/10/98
(Date)

Signature
(Signature of Inventor)
1/12/98
(Date)

C. M. - P. Rao
(Signature of Inventor)
1/12/98
(Date)

R. G. Mehta
(Signature of Inventor)
1/12/98
(Date)

89008957-012098

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF:)
 Robert M. Moriarty)
 Raju A. Penmasta)
 Liang Guo)
 Munagala S. Rao)
 Rajendra G. Mehta)
)
 SERIAL NO.:)
)
 FILED:)
)
 FOR: 1 α -HYDROXYVITAMIN D₅, ITS)
 SYNTHESIS AND USE IN CANCER)
 PREVENTION AND THERAPY)

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
 (37 CFR 1.9(f) & 1.27(b)) -- INDEPENDENT INVENTORS**

Box Patent Application
 Assistant Commissioner for Patents
 Washington, D.C. 20231

Sir:

As below named inventors, we hereby declare that we qualify as independent inventors as defined in 37 C.F.R. Section 1.9(c) for the purposes of paying reduced fees to the Patent and Trademark Office regarding the invention titled 1 α -HYDROXYVITAMIN D₅, ITS SYNTHESIS AND USE IN CANCER PREVENTION AND THERAPY described in the specification filed herewith.

We have not assigned, granted, conveyed or licensed and are under no obligation under contract law to assign, grant, convey or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 C.F.R. Section 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 C.F.R. Section 1.9(d) or a nonprofit organization under 37 C.F.R. Section 1.9(e).

Each person, concern, or organization to which we have assigned, granted, conveyed or licensed or are under obligation under contract or law to assign, grant, convey or license any rights in the invention is listed below:

Steroids, Ltd.

We acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of

09008957-013098

a) β -phase (100°C)		b) β -phase (100°C)		c) β -phase (100°C)		d) β -phase (100°C)		e) β -phase (100°C)		f) β -phase (100°C)		g) β -phase (100°C)		h) β -phase (100°C)		i) β -phase (100°C)		j) β -phase (100°C)		k) β -phase (100°C)		l) β -phase (100°C)		m) β -phase (100°C)		n) β -phase (100°C)		o) β -phase (100°C)		p) β -phase (100°C)		q) β -phase (100°C)		r) β -phase (100°C)		s) β -phase (100°C)		t) β -phase (100°C)		u) β -phase (100°C)		v) β -phase (100°C)		w) β -phase (100°C)		x) β -phase (100°C)		y) β -phase (100°C)		z) β -phase (100°C)																																																	
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

Name of Inventor:

Signature of Inventor:

Robert M. Mousley
1/11/98

* * * * *

Raju A. Penmasta

Signature of Inventor:

Rep Adams to

1/12/98

* * * * *

Liang Guo

Signature of Inventor:

Longford

1/12/98

* * * * *

Munagala S. Rao

Signature of Inventor:

Ch. S. Rao

11/12/98

* * * * *

Name of Inventor:

Rajendra G. Mehta

Signature of Inventor:

Raj Mehta

Date:

1/12/98

09008957 012098